Mannkind Corp
Research Mannkind Corp (MNKD) on Bullrun: market cap USD 1.29B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMNKD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.29B
- Financial periodQ2 2026
- RevenueUSD 109.38M
- Net income-USD 19.03M
- Free cash flow-USD 23.45M
- Gross margin73.0%
Valuation Snapshot
latest market cap is USD 1.29B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 348.97M | USD 5.86M | USD 13.69M | 92.3% | 0.02 | USD 74.88M | USD 354.64M | -USD 51.02M |
| FY2024 | USD 285.50M | USD 27.59M | USD 32.82M | 93.9% | 0.1 | USD 46.34M | USD 36.05M | -USD 78.82M |
| FY2023 | USD 198.96M | -USD 11.94M | -USD 8.35M | 89.5% | -0.04 | USD 238.48M | USD 268.70M | -USD 246.17M |
| FY2022 | USD 99.77M | -USD 87.40M | -USD 88.27M | 84.0% | -0.34 | USD 69.77M | USD 273.49M | -USD 250.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.29B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.75B | 283.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.95B | 71.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 981.25M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.39B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.10B | n/a | n/a | n/a |
About Mannkind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mannkind Corp's market cap?
Mannkind Corp's market capitalization is USD 1.29B.
What does Mannkind Corp do?
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.